Sanofi
SNY
USReal-Time PriceSanofi (SNY) Stock News
The latest Sanofi (SNY) news in one feed: earnings updates, analyst ratings, product launches and regulatory filings, curated and summarized by BTI.
Novavax's Selloff Puts the Sanofi Partnership Under the Microscope
Novavax fell harder than the broader biotech market as investors reconsidered a partner-led business. Sanofi gives the company reach, but royalty and milestone timing remain outside Novavax's control.
Recursion's Sanofi Milestone Comes With a $200 Million Dilution Trade-Off
Sanofi selected the first development candidate from its Recursion collaboration, triggering $10 million and shifting future development costs to Sanofi, while a simultaneous $200 million stock offering materially expands Recursion's share count.
Novavax's 12% Drop Exposes Its Dependence on Sanofi
Novavax fell 12% in a broad vaccine selloff, but its sharper risk is company-specific: royalties and milestones now depend heavily on Sanofi's commercial execution and timing.
Regeneron’s Sanofi Profit Share Is No Longer Paying Down the Past
Regeneron fully repaid its development balance to Sanofi at the end of the second quarter. From the third quarter, its collaboration revenue should reflect the full profit share, making the next report an unusually clean test.